The main purpose of this study is to evaluate the safety and tolerability of single and multiple ascending doses of RO7806881 in healthy participants.
Participants must be males or females who are overtly healthy as determined by medical evaluation
Participants must have body weight (BW) ≥ 40 kilograms (kg) (not applicable to Cohort A9) and body mass index (BMI) within the range 18-32 kilograms per square meter (kg/m²) (inclusive)
Must be of ethnic Chinese, Korean, or Japanese origin
Must have a BW >35 kg and BMI within the range 18-32 kg/m2 (inclusive)
Pregnancy, breastfeeding, or intention to become pregnant during the study or within 6 months after the final dose of study treatment
History of any clinically significant autoimmune, gastrointestinal, renal, hepatic, pulmonary, neurological, psychiatric, cardiovascular, endocrinological, hematological, or allergic disease; metabolic disorder; cancer or cirrhosis
Latent tuberculosis (TB) or potentially active TB
Any major illness within 1 month before the screening examination or any febrile illness within 1 week prior to the screening visit and up to first dose administration